GlassScriptPhysician profile
Craig M Ellison
NPI 1932254083
$7,472.51
in general payments reported to CMS, 2019-2025
30 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $497 · 2021: $890 · 2022: $1,461 · 2023: $1,272 · 2024: $1,178 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495 · Education: $87.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,495.44 |
| Education | $87.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,259.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,170.84 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $862.07 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $662.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $317.21 | 2019-2025 | |
| Genzyme Corporation | $298.05 | 2022-2025 | |
| Celgene Corporation | $265.89 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $228.34 | 2019-2024 | Rebyota |
| Gilead Sciences, INC. | $214.26 | 2022-2024 | |
| Ucb, INC. | $168.77 | 2019 | |
| Ironwood Pharmaceuticals, INC | $145.95 | 2021-2024 | Linzess |
| Lilly USA, LLC | $139.86 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $98.09 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $67.66 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $56.92 | 2024 | Zymfentra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $54.83 | 2021-2023 | |
| Qol Medical, LLC | $54.27 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $53.65 | 2024-2025 | Ibsrela |
| Romark Laboratories, Lc | $52.27 | 2020 | |
| Medtronic, INC. | $41.29 | 2022 | |
| Aimmune Therapeutics, INC. | $40.56 | 2025 | Zenpep |
| Stryker Corporation | $33.12 | 2025 | Neptune |
| Capsovision, INC. | $31.19 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $30.81 | 2019-2020 | |
| Braintree Laboratories, INC. | $30.09 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $25.81 | 2025 | Iqirvo |
| Novo Nordisk INC | $20.93 | 2025 | Wegovy |
| Shire North American Group INC | $17.14 | 2019 | |
| Vivus LLC | $16.12 | 2025 | Qsymia |
| Daiichi Sankyo INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.